Answers are grounded in this paper and cite their sources.
Background/Objectives: Multiparameter flow cytometry (MFC) is widely used for measurable residual disease (MRD) assessment in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The impact of analytical software on diagnostic performance remains underexplored. Methods: We compared BD FACSDiva, FlowJo, and Infinicyt using identical Flow Cytometry Standard (FCS) datasets from 76 bone marrow samples. Routine FACSDiva MRD classification served as the reference classification. Data was analyzed using an 8-color routine panel and a 14-color extended panel. Diagnostic performance was assessed using area under the curve (AUC), sensitivity, specificity, predictive values, overall accuracy, and agreement with the reference classification. Results: The 14-color panel showed higher sensitivity, negative predictive value (NPV), and overall accuracy than the 8-color panel across all evaluated software platforms, whereas specificity varied between platforms. FlowJo with the 14-color panel showed the highest numerical diagnostic performance (AUC = 0.917; overall accuracy = 97.37%) and the strongest agreement with the reference classification (κ = 0.894; 95% confidence interval [CI] = 0.794–1.000). Its NPV was significantly higher than that of Infinicyt (100% vs. 70.0%, p = 0.047), although other pairwise differences between software platforms were not statistically significant. Conclusions: The findings indicate that both panel dimensionality and analytical workflow influence flow cytometric MRD assessment. The extended 14-color panel improved detection performance across platforms, while software-dependent differences remained evident, highlighting the need for standardized post-acquisition analysis and independent validation.
No takes yet. Share an insight, caveat, or question.
Baldzhieva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: